Related Experiment Video

Updated: May 27, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children

Michael Leonardi1, Kenneth Bromberg, Roger Baxter

  • 1aPalmetto Pediatrics, North Charleston, SC, USA.

Pediatrics
|November 30, 2011
PubMed

Insights

Administering the measles, mumps, rubella, and varicella vaccine (MMRV) together with the pneumococcal 7-valent conjugate vaccine (PCV-7) to children is safe and effective. Both vaccines given at the same time produced similar immune responses compared to separate administrations.

Area of Science:

  • Pediatric infectious diseases
  • Vaccinology
  • Immunology

Background:

  • Childhood vaccination schedules aim to protect against serious infectious diseases.
  • The combination measles, mumps, rubella, and varicella vaccine (MMRV) and the pneumococcal 7-valent conjugate vaccine (PCV-7) are commonly administered to young children.
  • Assessing the safety and immunogenicity of co-administered vaccines is crucial for optimizing immunization strategies.

Purpose of the Study:

  • To evaluate the immunogenicity and safety of administering the MMRV vaccine concomitantly with the PCV-7 vaccine in healthy children.
  • To compare the immune responses and adverse events when MMRV and PCV-7 are given together versus sequentially.

Main Methods:

  • A randomized controlled trial involving 1027 healthy children aged 12 to 15 months.
  • Participants were assigned to receive MMRV and PCV-7 concomitantly (group 1) or sequentially with a 6-week interval (groups 2 and 3).
  • Immunogenicity was assessed by antibody response rates for all vaccine antigens, and safety was monitored for local and systemic adverse experiences.

Main Results:

  • High antibody response rates were observed for all antigens in both vaccines, with rates ≥96.8% for measles, mumps, and rubella, ≥88.0% for varicella-zoster virus, and ≥98.3% for all 7 pneumococcal serotypes.
  • Immune responses to MMRV and PCV-7 antigens were similar regardless of whether the vaccines were administered concomitantly or sequentially.
  • The incidence of adverse experiences was comparable between the concomitant group and the sequential groups, with no vaccine-related serious adverse events reported.

Conclusions:

  • Concomitant administration of MMRV and PCV-7 vaccines is highly immunogenic and well-tolerated in healthy children aged 12 to 15 months.
  • The findings support the simultaneous administration of MMRV and PCV-7 vaccines as a safe and effective immunization strategy.
  • Co-administration simplifies the vaccination schedule without compromising vaccine efficacy or safety.
Abstract

More Related Videos

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique09:37

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique

Published on: September 23, 2022

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...